Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Intensive Care Med ; 37(8): 1112-1116, 2022 Aug.
Article in English | MEDLINE | ID: mdl-34515566

ABSTRACT

We present a case of rapidly growing disseminated Mycobacterium tuberculosis (MTB) that presented as an empyema necessitans (EN) in a 65-year-old woman with a single right lung transplant admitted for progressive dyspnea. While hospitalized, she had daily fevers and was found to have a right-sided chest wall abscess and pleural effusion. Acid-fast bacilli cultures from the abscess and pleural fluid grew MTB within 4 and 6 days, respectively. Blood cultures later grew MTB as well. Upon initiation of rifampin, isoniazid, pyrazinamide, and ethambutol, she developed hemorrhagic pancreatitis and distributive shock secondary to antituberculosis medications and disseminated MTB. Noteworthy features of this case include the rapid rate of MTB culture growth in less than a week, the development of a likely donor-derived MTB EN, and the clinical challenges of MTB screening and MTB infection management in a solid organ transplant recipient.


Subject(s)
Empyema , Mycobacterium tuberculosis , Pleural Effusion , Abscess/complications , Abscess/drug therapy , Aged , Antitubercular Agents/therapeutic use , Empyema/complications , Empyema/drug therapy , Female , Humans , Pleural Effusion/etiology
2.
Curr Opin Infect Dis ; 27(5): 418-24, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25023742

ABSTRACT

PURPOSE OF REVIEW: The diagnosis and management of acute and chronic infections with the microorganism Trypanosoma cruzi, which causes Chagas disease, is important in solid organ transplantation in both endemic and nonendemic countries. In this review, we examine recently published data on the topic of Chagas disease in solid organ transplantation, with an emphasis on data relevant to heart transplantation. RECENT FINDINGS: Most people with chronic T. cruzi infection have the intermediate form of disease, but approximately 2% of infected persons will progress to Chagas cardiomyopathy per year. The risk of T. cruzi transmission with liver or kidney transplantation appears to be substantially less than that with heart transplantation. For patients with Chagas cardiomyopathy undergoing heart transplant, a structured clinical and laboratory monitoring protocol is necessary to monitor for T. cruzi reactivation. Recent data indicate that laboratory monitoring of peripheral blood with polymerase chain reaction testing can identify reactivation prior to the occurrence of symptoms and allograft injury. SUMMARY: Transplant clinicians should exercise vigilance in surveillance for Chagas disease in both organ donors and recipients. Although Chagas disease may seem uncommon, it is pervasive in endemic and several nonendemic countries, including the United States and Spain.


Subject(s)
Chagas Disease/prevention & control , Heart Transplantation/adverse effects , Liver Transplantation/adverse effects , Tissue Donors , Trypanosoma cruzi/isolation & purification , Chagas Disease/diagnosis , Chagas Disease/epidemiology , Humans , Population Surveillance , Prevalence , Public Health , Risk Assessment , Risk Factors , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...